US Inhaled Insulin Therapeutic Choice Questionnaire Study
|ClinicalTrials.gov Identifier: NCT00139763|
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : March 19, 2007
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
This study will also ask if patients with uncontrolled type 2 diabetes currently managed on diabetes pills + once daily insulin will choose as the next treatment choice to take insulin multiple times a day if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Procedure: Educational Materials||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||740 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A US Randomized Questionnaire-Based Trial Assessing The Impact Of The Availability Of Inhaled Insulin On Therapeutic Choice In Patients With Suboptimally Controlled Type 2 Diabetes|
|Study Start Date :||July 2005|
|Study Completion Date :||March 2006|
- Will availability of inhaled insulin result in more type 2 diabetes patients choosing a treatment that involves insulin (if now on >2 OAs) or a more intensive insulin regimen (if now on OAs + glargine) compared to only standard therapies available
- Determine both patient and MD reasons for treatment choices made. Determine if treatment choice is influenced by physician specialty or patient ethnicity. Determine how cost impacts patient treatment choice.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00139763
Show 42 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|